Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for M.I.Tech Co., Ltd. (179290:KRX), powered by AI.
M.I.Tech Co., Ltd. is currently trading at ₩4,970. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for M.I.Tech Co., Ltd. on Alpha Lenz.
M.I.Tech Co., Ltd.'s P/E ratio is 7.9.
“M.I.Tech Co., Ltd. trades at a P/E of 7.9 (undervalued) with strong ROE of 17.3%. Operating margin of 30.8% indicates strong profitability.”
Ask for details →M.I.Tech Co., Ltd. is a dynamic company operating within the medical device industry. Primarily focused on the research, development, and manufacturing of advanced stent systems, M.I.Tech caters to a significant sector that addresses critical medical needs. The company's products are crucial for various medical procedures, particularly in treating disorders such as esophageal, gastrointestinal, and vascular conditions. By providing innovative solutions, M.I.Tech plays a pivotal role in enhancing healthcare outcomes, improving the quality of life for patients worldwide. The company's dedication to advancing medical technology is evident in its commitment to employing cutting-edge research and stringent quality controls in its production processes. As such, M.I.Tech's contributions are crucial in the medical field, with its focus on innovation assisting in the evolution of minimally invasive surgical techniques. Its presence in the financial market highlights its growing influence and importance as a key player in the medical device sector, appealing to a broad range of stakeholders, from healthcare providers to patients seeking improved therapeutic solutions.
“M.I.Tech Co., Ltd. trades at a P/E of 7.9 (undervalued) with strong ROE of 17.3%. Operating margin of 30.8% indicates strong profitability.”
Ask for details →M.I.Tech Co., Ltd. (ticker: 179290) is a company listed on KRX in the Healthcare sector (Medical Instruments & Supplies). Market cap is $160.9B.
The current price is ₩4,970 with a P/E ratio of 7.91x and P/B of 1.28x.
ROE is 17.32% and operating margin is 30.79%. Annual revenue is $67.2B.